Martine Extermann1,2, Richard R Reich1,3, Marina Sehovic1. 1. Senior Adult Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 2. Dept of Oncology Sciences, University of South Florida, Tampa, Florida. 3. Department of Psychology, College of Arts and Sciences, University of South Florida Sarasota-Manatee, Sarasota, Florida.
Abstract
BACKGROUND: The National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) and adjustment rules after severe toxicity are derived by consensus, but to the authors' knowledge little is known regarding the determinants of toxicity recurrence, especially in the elderly. METHODS: The authors prospectively accrued 200 patients (aged ≥65 years) before chemotherapy. For those with CTCAE grade 3 to 4 nonhematologic or CTCAE grade 4 hematologic toxicities (severe toxicity), the duration and functional impact, treatment modifications, and severe toxicity recurrence were recorded. The regimen's toxicity was adjusted with the MAX2 index, the average of the most frequent grade 4 hematologic toxicities and the most frequent grade 3 to 4 nonhematologic toxicities reported in publications of a regimen. RESULTS: The median patient age was 73 years (range, 65-90 years). Among 163 patients who were evaluable for toxicity after ≥1 treatment cycle (receiving on average 4.73 cycles), 82 had severe toxicity, 10 were discontinued for toxicity, 6 were discontinued for other reasons, and 5 patients had died. Sixty-one patients received further chemotherapy: 41 without dose modification (16 with secondary prevention measures) and 20 with dose modifications. Without modification, 19 patients (46%) experienced toxicity recurrence (0 deaths). With modification, 7 patients (35%) experienced a toxicity recurrence (1 death). On univariate analysis, treatment intent, hospitalization, duration-adjusted activities of daily living (ADL), quality of life impact, and fatigue were associated with dose modification. ADL remained associated on multivariate analysis (P = .02). On univariate analysis for toxicity recurrence, Eastern Cooperative Oncology Group performance status and MAX2 score demonstrated an association, with only the latter found to remain statistically significant on multivariate analysis (P = .04). CONCLUSIONS: If a severe toxicity does not have a long duration of impact on ADL, oncologists are less inclined to modify treatment. With proper supportive measures, this leads to recurrence risks similar to those shown in patients with modified treatment, with low risks of toxic deaths overall.
BACKGROUND: The National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) and adjustment rules after severe toxicity are derived by consensus, but to the authors' knowledge little is known regarding the determinants of toxicity recurrence, especially in the elderly. METHODS: The authors prospectively accrued 200 patients (aged ≥65 years) before chemotherapy. For those with CTCAE grade 3 to 4 nonhematologic or CTCAE grade 4 hematologic toxicities (severe toxicity), the duration and functional impact, treatment modifications, and severe toxicity recurrence were recorded. The regimen's toxicity was adjusted with the MAX2 index, the average of the most frequent grade 4 hematologic toxicities and the most frequent grade 3 to 4 nonhematologic toxicities reported in publications of a regimen. RESULTS: The median patient age was 73 years (range, 65-90 years). Among 163 patients who were evaluable for toxicity after ≥1 treatment cycle (receiving on average 4.73 cycles), 82 had severe toxicity, 10 were discontinued for toxicity, 6 were discontinued for other reasons, and 5 patients had died. Sixty-one patients received further chemotherapy: 41 without dose modification (16 with secondary prevention measures) and 20 with dose modifications. Without modification, 19 patients (46%) experienced toxicity recurrence (0 deaths). With modification, 7 patients (35%) experienced a toxicity recurrence (1 death). On univariate analysis, treatment intent, hospitalization, duration-adjusted activities of daily living (ADL), quality of life impact, and fatigue were associated with dose modification. ADL remained associated on multivariate analysis (P = .02). On univariate analysis for toxicity recurrence, Eastern Cooperative Oncology Group performance status and MAX2 score demonstrated an association, with only the latter found to remain statistically significant on multivariate analysis (P = .04). CONCLUSIONS: If a severe toxicity does not have a long duration of impact on ADL, oncologists are less inclined to modify treatment. With proper supportive measures, this leads to recurrence risks similar to those shown in patients with modified treatment, with low risks of toxic deaths overall.
Keywords:
Common Terminology Criteria for Adverse Events (CTCAE); MAX2 index; chemotherapy; chemotherapy toxicity; elderly; functional status; geriatric oncology; management of chemotherapy toxicity; quality of life
Authors: Martine Extermann; Ivette Boler; Richard R Reich; Gary H Lyman; Richard H Brown; Joseph DeFelice; Richard M Levine; Eric T Lubiner; Pablo Reyes; Frederic J Schreiber; Lodovico Balducci Journal: Cancer Date: 2011-11-09 Impact factor: 6.860
Authors: Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew Journal: J Clin Oncol Date: 2011-08-01 Impact factor: 44.544
Authors: M D Miller; C F Paradis; P R Houck; S Mazumdar; J A Stack; A H Rifai; B Mulsant; C F Reynolds Journal: Psychiatry Res Date: 1992-03 Impact factor: 3.222
Authors: A A Aaldriks; E Maartense; S le Cessie; E J Giltay; H A C M Verlaan; L G M van der Geest; W M Kloosterman-Boele; M T Peters-Dijkshoorn; B A Blansjaar; H W van Schaick; J W R Nortier Journal: Crit Rev Oncol Hematol Date: 2010-08-14 Impact factor: 6.312
Authors: D M Hann; P B Jacobsen; L M Azzarello; S C Martin; S L Curran; K K Fields; H Greenberg; G Lyman Journal: Qual Life Res Date: 1998-05 Impact factor: 4.147
Authors: M Extermann; H Chen; A B Cantor; M B Corcoran; J Meyer; E Grendys; D Cavanaugh; S Antonek; A Camarata; W E Haley; L Balducci Journal: Eur J Cancer Date: 2002-07 Impact factor: 9.162
Authors: Gilles Freyer; Nicolas Jovenin; Gabriel Yazbek; Christian Villanueva; Amal Hussain; Anne Berthune; Maciej Rotarski; Hèlène Simon; Vincent Boulanger; Michael Hummelsberger; Claire Falandry Journal: Anticancer Res Date: 2013-01 Impact factor: 2.480
Authors: Victoria Wochna Loerzel; Robert B Hines; Christine Wargo Deatrick; Patricia I Geddie; John M Clochesy Journal: Support Care Cancer Date: 2021-06-09 Impact factor: 3.603
Authors: Alissa Nolden; Paule V Joseph; Kord M Kober; Bruce A Cooper; Steven M Paul; Marilyn J Hammer; Laura B Dunn; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2019-07-23 Impact factor: 3.612
Authors: Inger Utne; Borghild Løyland; Ellen Karine Grov; Hege Lund Rasmussen; Ann Helen Torstveit; Bruce A Cooper; Judy Mastick; Melissa Mazor; Melisa Wong; Steven M Paul; Yvette P Conley; Thierry Jahan; Christine Ritchie; Jon D Levine; Christine Miaskowski Journal: Eur J Oncol Nurs Date: 2018-08-22 Impact factor: 2.398
Authors: Inger Utne; Bruce A Cooper; Christine Ritchie; Melisa Wong; Laura B Dunn; Borghild Loyland; Ellen Karine Grov; Marilyn J Hammer; Steven M Paul; Jon D Levine; Yvette P Conley; Kord M Kober; Christine Miaskowski Journal: Eur J Oncol Nurs Date: 2020-08-03 Impact factor: 2.398
Authors: Rebecca S Meltzer; David A Kooby; Jeffrey M Switchenko; Jashodeep Datta; Darren R Carpizo; Shishir K Maithel; Mihir M Shah Journal: Ann Surg Oncol Date: 2020-11-03 Impact factor: 5.344
Authors: Inger Utne; Borghild Løyland; Ellen Karine Grov; Steven Paul; Melisa L Wong; Yvette P Conley; Bruce A Cooper; Jon D Levine; Christine Miaskowski Journal: Eur J Oncol Nurs Date: 2019-07-02 Impact factor: 2.398
Authors: Kord M Kober; Ritu Roy; Anand Dhruva; Yvette P Conley; Raymond J Chan; Bruce Cooper; Adam Olshen; Christine Miaskowski Journal: Fatigue Date: 2021-02-16
Authors: Marie A Flannery; Eva Culakova; Beverly E Canin; Luke Peppone; Erika Ramsdale; Supriya G Mohile Journal: J Clin Oncol Date: 2021-05-27 Impact factor: 44.544